BACKGROUND: Capecitabine with oxaliplatin (CAPOX) has previously demonstrated clinical activity in patients with small bowel adenocarcinoma (SBA) and ampullary adenocarcinoma (AAC). Herein, the authors conducted a phase 2 trial to evaluate the benefit of adding bevacizumab to CAPOX. .0]). The probability of PFS at 6 months was 68% (95% confidence interval [95% CI], 52% to 88%). The response rate was 48.3%, with 1 complete response and 13 partial responses; 10 patients achieved stable disease. At a median follow-up of 25.9 months, the median PFS was 8.7 months (95% CI, 4.9-10.5 months) and the median overall survival was 12.9 months (95% CI, 9.2-19.7 months). CONCLUSIONS: The results of the current study indicate that CAPOX with bevacizumab is an active and well-tolerated regimen for patients with SBA and AAC. These findings support the need for further investigation into the clinical benefit of targeting angiogenesis in patients with SBA and AAC. Cancer 2017;123:1011-7.
INTRODUCTION
Small bowel adenocarcinoma (SBA) and ampullary adenocarcinoma (AAC) are rare tumors. The estimated incidence of small bowel cancer in the United States for 2016 is 10,090 patients; of these cases, approximately 40% will be adenocarcinomas. 1, 2 The vast majority of patients present with late-stage disease, which in part relates to frequent delays in diagnosis. 2 Although to the best of our knowledge there are no randomized clinical trials comparing the efficacy of various chemotherapy regimens in patients with SBA, there have been 4 prospective studies, 3 of which used fluoropyrimidine and oxaliplatin as the backbone of chemotherapy. [3] [4] [5] [6] We previously demonstrated that capecitabine with oxaliplatin (CAPOX) is a safe and effective regimen for the treatment of both advanced SBA and AAC. 4 
Original Article
Vascular endothelial growth factor (VEGF) plays a key role in tumor-associated neoangiogenesis, which helps to provide a tumor with oxygen and nutrition and supports the development of metastasis. 7 We previously conducted immunohistochemical staining for VEGF-A on 54 SBA tumor samples and found that VEGF-A was expressed in 96% of cases. 8 Another study noted the universal expression of VEGF-A messenger RNA in 56 SBA samples at significantly higher levels compared with levels in adjacent normal intestinal mucosa. 9 To our knowledge, the role of VEGF-targeted agents has not been prospectively studied in the treatment of patients with SBA and AAC.
Bevacizumab, which is approved by the US Food and Drug Administration, is a recombinant humanized monoclonal immunoglobulin G antibody that binds to VEGF-A and prevents its binding to receptors on endothelial and cancer cells. 10 The combination of CAPOX and bevacizumab has been studied extensively in colorectal cancer (CRC), and has been approved by the Food and Drug Administration for the first-line treatment of patients with metastatic CRC. A phase 3 study comparing bevacizumab plus leucovorin, 5-fluorouracil (5-FU), and oxaliplatin (FOLFOX)/CAPOX with placebo plus FOL-FOX/CAPOX demonstrated similar rates of grade 3 to 4 toxicity; however, the addition of bevacizumab was found to improve outcomes, with a median progression-free survival (PFS) of 9.4 months with bevacizumab compared with 8 months with placebo. 11 Given the high level of expression of VEGF-A in metastatic SBA and AAC taken together with the benefit noted with the addition of bevacizumab to chemotherapy in patients with metastatic CRC, we hypothesized that the addition of bevacizumab to CAPOX chemotherapy would improve anticancer activity and improve outcomes for patients with these malignancies.
MATERIALS AND METHODS

Patients
All eligible patients were required to have histologically confirmed SBA or AAC; measurable metastatic disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria 12 ; an Eastern Cooperative Oncology Group performance status of 0 to 2; and adequate hematologic (absolute neutrophil count 1500/lL and platelet count 100,000/lL), hepatic (total bilirubin 1.5 times the upper limit of normal and aspartate aminotransferase and alanine aminotransferase <3 times the upper limit of normal), and renal function (creatinine clearance > 50 mL/minute). Prior adjuvant chemotherapy (including 5-FU, capecitabine, and oxaliplatin) was permitted if completed 52 weeks prior and previous capecitabine or 5-FU administered as a radiosensitizing agent was allowed. A minimum of 4 weeks must have elapsed from the time of completion of any prior chemotherapy, radiotherapy, or surgery. Patients with any of the following were not eligible to participate in the current study: prior chemotherapy for metastatic disease; a known history of dihydropyrimidine deficiency; peripheral neuropathy of grade 3; inadequately controlled hypertension (systolic blood pressure > 140 mm Hg and/or diastolic blood pressure >90 mm Hg) or a history of hypertensive crisis/encephalopathy; New York Heart Association class II congestive heart failure; and myocardial infarction, unstable angina, cerebrovascular accident, transient ischemic attack, or significant vascular disease within the previous 6 months. The Institutional Review Board of The University of Texas MD Anderson Cancer Center approved the study protocol and all patients provided written informed consent.
Study Design
The current study was an open-label, single-arm, singleinstitution, phase 2 study conducted at The University of Texas MD Anderson Cancer Center. Treatment consisted of intravenous oxaliplatin (at a dose of 130 mg/m 2 ) administered on day 1, intravenous bevacizumab (at a dose of 7.5 mg/kg) administered on day 1, and oral capecitabine (at a dose of 1500 mg/m 2 ) divided twice daily on days 1 to 14 of each treatment cycle. Treatment cycles were repeated every 21 days and imaging studies were conducted every 3 cycles. Treatment was continued until disease progression, intercurrent illness preventing the further administration of treatments, severe predefined treatment-related toxicities, or a treatment delay of >4 weeks due to toxicity.
Dose Reductions
Toxicity was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0), except for neurosensory and skin toxicity. Neurosensory toxicity was graded according to the Neurologic Toxicity Scale for Oxaliplatin Dose Adjustments. Neurosensory toxicity did not result in dose reductions for capecitabine or bevacizumab. A new cycle of chemotherapy with capecitabine, oxaliplatin, and bevacizumab was delayed until the absolute neutrophil count was 1000/mm 3 ; the platelet count was 75,000/mm related neurosensory toxicity) to baseline or was grade 1. Treatment with capecitabine was interrupted during a cycle for grade 3 or 4 hematologic toxicities (excluding anemia) or for grade 2 non-hematologic toxicities (excluding grade 2 nausea or vomiting). The capecitabine dose was reduced by 25% for grade 2 hand-foot syndrome and by 50% for grade 3 hand-foot syndrome, by 25% for grade 3 non-hematologic toxicities and by 50% for grade 4 non-hematologic toxicities, and by 25% for a delay in hematologic recovery of 1 week (excluding anemia). The oxaliplatin dose was reduced by 25% for grade 3 or 4 hematologic toxicities (excluding anemia), grade 3 or 4 nonhematologic toxicities (excluding hand-foot syndrome), a delay in hematologic recovery of 1 week (excluding anemia), or paresthesias with pain or functional impairment of 7 days. Oxaliplatin was discontinued if paresthesias with pain or functional impairment persisted throughout a cycle. Patients were allowed to continue on the study after discontinuation of oxaliplatin. Two dose reductions were allowed for capecitabine and oxaliplatin. If a third reduction was required, the patient was removed from the study. There were no dose adjustments for bevacizumab.
Statistical Analysis
The primary endpoint was PFS at 6 months. PFS was defined as the interval between the initiation of treatment and the date of first documentation of disease progression or symptomatic deterioration or death due to any cause. A previous study with 25 patients who were treated with CAPOX alone demonstrated a PFS rate at 6 months of 52%. 4 The accrual goal for the current study was 30 patients. This sample size ensured that, if the trial was not terminated early, a posterior 90% confidence interval (90% CI) of PFS at 6 months would be 0.52 to 0.79, assuming that the PFS at 6 months would be 0.67 (20 out of 30 patients) with the new treatment.
Secondary endpoints included response rate (RR), overall PFS, overall survival (OS), and toxicity. Responses were determined according to RECIST criteria in all evaluable patients. Toxicity data were analyzed in all patients who received at least 1 dose of the study medication. For the unplanned exploratory analysis, we analyzed historical data from the metastatic cohort (25 patients) from our previous CAPOX study. 4 Both sets of patients, current and historical, had metastatic disease.
OS was defined as the time from the first study treatment to the date of death or last follow-up. Comparisons were conducted using the Wilcoxon rank sum test, Fisher exact test, or log-rank test. Kaplan-Meier curves were used to estimate unadjusted OS and PFS time distributions. All computations were performed using SAS statistical software (version 9.4; SAS Institute Inc, Cary, NC) and TIBCO Spotfire S 1 (version 8.2; TIBCO Software Inc, Palo Alto, Calif).
RESULTS
Between August 2011 and November 2014, a total of 30 patients with advanced SBA or AAC were enrolled. The baseline characteristics of the study population are listed in Table 1 . The median age of the study population was 63 years. Of the 30 patients, 23 (77%) had SBA (18 of duodenal origin and 5 of jejunal/ileal origin) whereas 7 patients (23%) had AAC (5 of pancreatobiliary subtype, 1 of intestinal subtype, and 1 of mixed subtype). Poorly differentiated histology was present in 60% of patients and mucinous histology was present in 16.7%. Inflammatory bowel disease was present in 1 patient, whereas none of the patients had a known history of Lynch syndrome.
Outcomes related to the efficacy of this regimen are listed in Table 2 . The primary endpoint for the current study was PFS at 6 months. The probability of PFS at 6 months with the combination of CAPOX and bevacizumab was 68% (95% CI, 52%-88%; 90% CI, 54%-84%). Secondary endpoints included overall RR (ORR), overall PFS, and OS. The ORR was 48.3% with 1 complete response (CR) and 13 partial responses (PRs). Ten patients had stable disease (SD). The 1 unevaluable patient received 1 cycle of the study treatment for metastatic duodenal adenocarcinoma, but due to the development of duodenal obstruction and biliary obstruction with a subsequent decline in performance status, the patient was deemed not to be a candidate for additional chemotherapy. Figure 1 depicts a waterfall plot of best tumor response as per RECIST criteria. The patient with a CR was diagnosed with AAC of pancreatobiliary subtype and achieved a CR in multiple liver metastases after 12 cycles of CAPOX and bevacizumab and remained in CR for an additional 10 months. A second patient with duodenal adenocarcinoma developed radiographic resolution of extensive mesenteric and retroperitoneal lymphadenopathy but due to an elevated tumor marker was categorized as having achieved a PR and remained on study at the time of last follow-up, 15 months from the initiation of the study. The RR was similar between patients with SBA (50%) and those with AAC (43%). Of the 5 patients with AAC of pancreatobiliary subtype, 1 patient achieved a CR as noted above, another patient achieved a PR, and the remaining 3 patients had SD as their best response to treatment with CAPOX and bevacizumab. The best response achieved by the patient with AAC of intestinal subtype was a PR and the best response achieved by the patient with AAC of mixed subtype was SD. At a median follow-up of 25.9 months, the median PFS was 8.7 months (95% CI, 4.9-10.5 months; 90% CI, 6.5-10.3 months) and the median OS was 12.9 months (95% CI, 9.2-19.7 months; 90% CI, 10.5-17.2 months) ( Fig. 2) (Table 2) . At the time of last follow-up, 3 patients remained on the current study.
The most common treatment-related grade 1 to 4 adverse events are listed in Table 3 . Treatment was well tolerated, with the most common grade 3 toxicities being fatigue (7 patients; 23%), hypertension (7 patients; 23%), neutropenia (6 patients; 20%), and diarrhea (3 patients; 10%). Common grade 2 toxicities were anorexia (15 patients; 50%), fatigue (14 patients; 47%), and nausea (11 patients; 37%). Only one grade 4 toxicity occurred; this patient developed grade 4 neutropenia after 8 cycles of treatment. There were no treatment-related deaths reported. An exploratory analysis comparing the current study with the metastatic cohort of 25 patients from our prior phase 2 CAPOX study 4 Fig. 1) .
DISCUSSION
In the current study, we demonstrated that the combination of CAPOX with bevacizumab is an active regimen, with an ORR of 48.3%, a median PFS of 8.7 months, and a median OS of 12.9 months. Treatment was well tolerated, with the most common grade 3 toxicities reported to be fatigue (23%), hypertension (23%), neutropenia (20%), and diarrhea (10%). The findings of the current study demonstrate that CAPOX with bevacizumab is a safe and efficacious combination for patients with advanced SBA or AAC. To the best of our knowledge, the current study is the first prospective clinical trial to date evaluating the use of targeted therapies in patients with SBA and AAC.
Based on phase 2 clinical trials and retrospective data, the standard first-line treatment regimen for patients with SBA is a combination of a fluoropyrimidine and oxaliplatin. [3] [4] [5] [6] The results from phase 2 studies of CAPOX and FOLFOX appear similar, with response rates of 39% to 52% and a median PFS of 7.8 to 11.3 months reported. 4, 6 Recently, the addition of irinotecan to CAPOX was explored, resulting in a median PFS of 8.7 months and a median OS of 12.7 months. 5 The results from the current study appear to be similar to those of these prior studies. In addition, toxicity was similar to that reported in prior studies with this treatment combination and, despite the presence of intact small bowel primary tumors in approximately 60% of the study patients, there were no episodes of bowel perforation reported.
Given its rarity and proximity to the large bowel, SBA often has been treated in a similar manner to CRC. 2 However, there are several epidemiological and molecular differences between SBA and CRC. According to Surveillance, Epidemiology, and End Results program data, stage IV disease is present in 32% of SBA cases, in contrast to 20% of CRC cases. 13 Furthermore, poor differentiation is present in 33% of SBA cases, in contrast to 21% of CRC cases. 13 The incidence of these malignancies is diverging, with the incidence of SBA increasing and that of CRC declining in the United States 2 ; however, it should be noted that there is no routine screening for SBA and AAC whereas there are strict screening guidelines for CRC. In addition, recent work has demonstrated that the stagestratified, cancer-specific survival rate was worse for patients with SBA than for those with CRC. 13 Although less is known regarding the molecular basis of SBA, the rate of APC mutations is markedly less, ranging from 7% to 13%, in contrast to 60% to 68% in CRC.
2 SMAD4 mutations are more common in patients with SBA (30%) compared with those with CRC (5%-16%).
2 BRAF V600E mutations are very rare in individuals with SBA, with 1 study finding no BRAF mutations among 99 cases. 14 The rate of KRAS mutations (codons 12 and 13) in patients with SBA (40%-60%) is comparable to that in patients with CRC. 2 Taken together, such fundamental differences support continued efforts to better understand this malignancy and determine the optimal treatment approach.
An exploratory analysis comparing the current study with a preceding phase 2 clinical trial of CAPOX alone in patients with SBA and AAC that was conducted at the same institution demonstrated no significant difference in RR or PFS. However, it is important to note that both studies enrolled a limited number of patients and were not designed or powered to detect differences between the 2 regimens. The benefit of the addition of bevacizumab to chemotherapy in patients with CRC has been demonstrated in several large randomized trials. The most recent international phase 3 clinical trial (NO16966) comparing bevacizumab or placebo combined with FOLFOX/ CAPOX in the first-line setting demonstrated that the addition of bevacizumab improved outcome, with a median PFS of 9.4 months with bevacizumab compared with 8 months with placebo (HR, 0.83; P 5 .0023). 11 The median OS was 21.3 months in the group receiving bevacizumab and 19.9 months in the placebo group (HR, 0.89; P 5 .077). RRs were similar in both arms: 47% in the bevacizumab group and 49% in the placebo group (P 5 .31). It is interesting to note that, to the best of our knowledge, phase 3 clinical trials in gastric cancer have not demonstrated a benefit with the addition of bevacizumab. The AVAGAST phase 3 clinical trial comparing bevacizumab or placebo combined with cisplatin/capecitabine in the first-line setting failed to meet its primary endpoint, with a median OS of 12.1 months reported with bevacizumab compared with 10.1 months noted with placebo (HR, 0.87; P 5 .1002). 15 The median PFS was significantly improved from 5.3 months with placebo to 6.7 months with bevacizumab (HR, 0.80; P 5 .0037). The RR also was found to be significantly improved from 37.4% with placebo to 46% with bevacizumab (P 5 .0315). The results from this study, taken together with data from other studies of alimentary tract adenocarcinomas, suggest the rationale for the further evaluation of VEGF targeting in patients with SBA and AAC. However, further investigation will require large multicenter efforts to provide the needed comparative data within this disease type.
The results of the current study demonstrate the feasibility of completing prospective clinical trials of novel targeted agents in patients with orphan tumor types. Although the current study findings have suggested a novel combination therapy for this rare malignancy, they also raise an important question regarding the usefulness of costly targeted therapies in a population of patients for whom there are no randomized clinical trials. Recent successful efforts to target rare subsets of common tumors support the potential for improved clinical trial enrollment for patients with rare cancers. However, currently, oncologists and the patients they treat must rely on phase 2 clinical trials to guide treatment decisions.
The combination of CAPOX and bevacizumab appears to be an efficacious and well-tolerated regimen in patients with SBA and AAC. Toxicities were limited, and there were no treatment-related deaths reported. Further exploration of antiangiogenic approaches in individuals with SBA and AAC is warranted.
FUNDING SUPPORT
Financial support provided by Roche/Genentech and the Kavanagh Family Foundation.
